Inactive Instrument

AVEO Pharmaceuticals, Inc. Stock price

Equities

AVEO

US0535883070

Pharmaceuticals

Dynamic Chart
AVEO Pharmaceuticals, Inc. Announces Executive Changes CI
Aveo Oncology Announces Publication of Long-Term Survival in Patients with Relapsed/Refractory Advanced Renal Cell Carcinoma Treated with Tivozanib: Analysis of the Phase Iii Tivo-3 Trial in the Oncologist CI
AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) CI
AVEO Oncology Announces Completion of Enrollment in Pivotal Phase 3 TiNivo-2 Study of FOTIVDA(R) in Combination with OPDIVO(R) in Advanced Renal Cell Carcinoma CI
South Korean Stocks Climb on Demand Recovery Hopes from China; LG Chem Stocks Add 1% MT
AVEO Completes Acquisition by LG Chem MT
LG Chem Acquires US Biopharma Firm AVEO Pharmaceuticals MT
AVEO Pharmaceuticals, Inc. Announces Management Changes CI
AVEO Oncology Appoints Martin Birkhofer as Its Chief Medical Officer CI
AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from NASDAQ Composite Index CI
AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from S&P Global BMI Index CI
AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from S&P TMI Index CI
LG Chem, Ltd. completed the acquisition of AVEO Pharmaceuticals, Inc. from a group of shareholders. CI
AVEO Pharmaceuticals Receives CFIUS Clearance for LG Chem Merger MT
AVEO Pharmaceuticals Stockholders Approve LG Chem Merger MT
More news
Managers TitleAgeSince
Chief Executive Officer 58 10-09-12
Director of Finance/CFO - -
Compliance Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 58 10-09-12
Director/Board Member - 23-01-18
More insiders
AVEO Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The Company is focused on delivering medicines for patients with cancer. The Company's commercial product include FOTIVDA (tivozanib), which is an oral, vascular endothelial growth factor receptor (VEGFR) and tyrosine kinase inhibitor (TKI). The Company markets FOTIVDA (tivozanib) in the United States for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. It also develops FOTIVDA in immuno-oncology combinations in refractory RCC and other indications and has several other investigational programs in clinical development. The Company's pipeline of product candidates includes ficlatuzumab, AV-380, AV-203 and AV-353. Its ficlatuzumab is a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF).
More about the company
  1. Stock
  2. Equities
  3. Stock AVEO Pharmaceuticals, Inc. - Nasdaq